Navitoclax dihydrochloride is under clinical development by AbbVie and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 10% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Navitoclax dihydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Navitoclax dihydrochloride overview

Navitoclax (ABT-263, RG7433) is under development for the treatment of primary myelofibrosis, metastatic melanoma, acute lymphoblastic leukemia, solid tumor, relapsed/refractory acute myeloid leukemia, non-small cell lung cancer, post polycythemia vera myelofibrosis, hepatocellular carcinoma, acute lymphocytic leukemia, lymphoblastic lymphoma and post-essential thrombocythemia myelofibrosis. It is administered orally. The drug candidate blocks the function of pro-survival Bcl-2 family proteins.

It was also under development for the treatment of small-cell lung cancer, metastatic hormone-refractory prostate cancer, hematologic malignancies including front-line chronic lymphocytic leukemia, relapsed or refractory chronic lymphocytic leukemia, myelofibrosis, primary myelofibrosis, post-polycythemia vera myelofibrosis, post-essential thrombocythemia myelofibrosis, polycythemia vera and essential thrombocythemia, B-cell chronic lymphocytic leukemia (CLL), relapsed diffuse large B-cell lymphoma and relapsed or refractory lymphoid malignancies and multiple myeloma.

AbbVie overview

AbbVie is a specialty biopharmaceutical company, which discovers, develops, manufactures, and commercializes drugs for the treatment of chronic and complex diseases. Its drugs are indicated for the treatment of metabolic diseases, rheumatological diseases, neurological disorders, viral diseases, skin diseases, complications associated with cystic fibrosis, pain related to endometriosis, diseases of the gastrointestinal tract, various types of cancer, and other serious health conditions. AbbVie is also advancing its pipeline programs for the treatment of cystic fibrosis, women’s health, various cancers, neurological disorders and other autoimmune diseases. The company markets its products directly to wholesalers, distributors, health care facilities, government agencies, specialty pharmacies and independent retailers through its own distribution centers and public warehouses worldwide. AbbVie is headquartered in North Chicago, Illinois, the US.

For a complete picture of Navitoclax dihydrochloride’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.